Drug Profile
Research programme: influenza monoclonal antibody therapeutics - ContraFect/Mount Sinai School of Medicine
Latest Information Update: 19 Sep 2014
Price :
$50
*
At a glance
- Originator Icahn School of Medicine at Mount Sinai
- Developer ContraFect; Icahn School of Medicine at Mount Sinai
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza virus infections